WebAcquired/ Merged Employees 302 Latest Deal Type M&A Latest Deal Amount $22B Investors 3 General Information Description Dicerna Pharmaceuticals is a … WebDec 27, 2024 · Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. The Company's GalXC RNAi technology Platform …
Pharmaceutical Companies Deals and acquisitions Sanofi
Web1 day ago · In late 2024, it agreed to spend north of $3 billion on Dicerna Pharmaceuticals, a company specialized in so-called RNA interference. And in 2024, it picked up Forma Therapeutics in a $1 billion deal that provided an experimental drug for sickle cell disease in late-stage clinical testing. WebDicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. ... --Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire ... pool shock treatment round rock tx
Novo Nordisk Announces Completion of Dicerna Pharmaceuticals …
WebNov 19, 2024 · Novo Nordisk has signed a definitive agreement for the acquisition of Dicerna Pharmaceuticals, including its ribonucleic acid interference (RNAi) platform, for a … WebMar 14, 2024 · Novo Nordisk acquired Dicerna Pharmaceuticals. Novo Nordisk has announced that it has completed the acquisition of Dicerna Pharmaceuticals. Novo Nordisk acquired Dicerna by paying USD 38.25 per share in cash. With the acquisition, Dicerna Pharmaceuticals became a subsidy of Novo Nordisk. WebAt the completion of the merger, Dicerna became a wholly owned subsidiary of Novo Nordisk. The common stock of Dicerna will no longer be listed or traded on the Nasdaq … sharedesite renaud